Pharmaceutical manufacturing to reach US$673.6bn by 2027

By Georgia Wilson
Share
ResearchAndMarkets.com's latest report reveals that the global pharmaceutical manufacturing industry is expected to reach US$673.6bn by 2027...

Titled the ‘Global Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Region: Trend Forecast and Growth Opportunity’, ResearchAndMarkets.com's latest report reveals that the global pharmaceutical manufacturing industry is expected to reach US$673.6bn by 2027, growing by 12.5% annually. 

Based on comprehensive research of the global pharmaceutical manufacturing industry, the report findings are said to be driven by five key areas: 

  • Increased drug approval
  • Increasing chronic ailments 
  • A growing geriatric population 
  • High research and development investments, 
  • Increasing healthcare expenditure as a result of COVID-19

ResearchAndMarkets.com outlook for the global industry is forecasted with optimistic, balanced and conservative views, taking into account the impact of COVID-19.

In the report, ResearchAndMarkets.com covers competitive scenarios and predicted trends, as well as the profiles of key vendors, leaders and emerging players in the markets, and the potential risks associated with investing in the global pharmaceutical manufacturing industry. 

ResearchAndMarkets.com has also generated Critical Success Factors (CSFs) to provide investors & stockholders with guidance when it comes to identifying emerging opportunities, managing and minimising the risks, developing appropriate business models, and making wise strategies and decisions.

Key players in the industry include: Abbott Laboratories, Aenova Group, Amgen, AstraZeneca, Catalent Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, GlaxoSmithKline plc, Johnson & Johnson, Lonza Group, Lupin, Merck & Co. Inc., Novartis AG, Novo Nordisk, Pfizer, Inc., Roche, Sanofi SA, and Takeda.

For more information on the full pharmaceutical manufacturing industry report, click here!

For more information on manufacturing topics - please take a look at the latest edition of Manufacturing Global.

Follow us on LinkedIn and Twitter.

Share

Featured Articles

Stellantis & CATL Boost EV Manufacturing Capacity

Stellantis & CATL intend to build US$4.43bn LFP battery plant in Spain by 2026, boosting EV production & advancing sustainable manufacturing

Sir David McMurty: A Visionary Engineer, Inventor and Leader

Sir David McMurty, Co-Founder of Renishaw has passed, leaving a legacy of manufacturing achievement, creating inventions and a unique company culture

IFS: Gaining New Manufacturing Value with Service Centricity

Leaders like IFS are empowering manufacturers to unlock significant business value with outcome-based service models, supercharging their customer service

Your Guide to Manufacturing LIVE Chicago

Procurement & Supply Chain

UPDATED VENUE & DATE – Manufacturing LIVE Chicago 2025

Sustainability & ESG

The Breakdown of the Global Plastics Treaty isn't the end

Sustainability & ESG